73 2021 ESG Report Transparency Responsible supply chain Product impact Climate change Introduction Healthy workforce and communities Appendices AMR is preventable: the role of infection prevention By partnering in prevention training and supporting infection control guidelines, BD is leveraging its expertise in diagnostics, vascular access, surgical preparation and critical care to support hospitals’ infection prevention and control programs. BD is committed to helping clinicians improve patient outcomes through the standardization of care and adherence to best practices. • In support of the inf ection prevention efforts of the Society for Healthcare Epidemiology of America (SHEA), BD has provided an educational grant for the “Prevention Course in HAI Knowledge and Control”—a free educational resource that provides critical information and skills to keep frontline providers, their families and patients safe. As of December 2021, there have been 1,600 enrollments in the course. • BD has partner ed with clinicians in addressing vascular access related complications by identifying gaps in their current vascular access process. Globally, in 2021, we completed over 200 assessments. • BD has w orked in collaboration with national governments in multiple countries, including the United States, China, Kenya, Cambodia and India, via public- private partnerships, to improve hospitals’ capabilities with infection prevention and control. AMR is real: the role of surveillance As we’ve seen with the COVID-19 pandemic, comprehensive surveillance is critical in identifying and responding to emerging threats to public health around the world. Surveillance is needed to understand the scope and risk of drug-resistant infections and to catch emerging threats when and where they arise—and develop an appropriate and effective response. • T he BD HealthSight™ platform leverages data to produce meaningful analytics and insights for clients, BD’s business units and the scientific community/ industry. With over 2.3 billion patient messages per year, we transform these data points into client analytic reports, poster presentations and peer-reviewed publications. We collaborate with other life science companies to publish these critical data sets. • T his data was integrated into the CDC’s “Antibiotic Resistance Threats Report,” highlighting the prevalence and impact of antibiotic-resistant bacteria and fungi on patients in the United States, and the Lancet ’s report, “Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.” 22 AMR is urgent: the role of diagnostic and antibiotic stewardship Antimicrobial stewardship programs in healthcare settings are designed to optimize antibiotic therapies, with the intention of slowing the emergence of drug resistance. Accurate and rapid diagnostic testing is a crucial element of stewardship. Diagnostic testing can identify the infection-causing organism, determine whether it is resistant and guide the appropriate therapeutic choice. • As part of the V alue-DX consortium, we have partnered on projects to assess the impact of point-of-care diagnostic testing in reducing the overuse of antibiotics. • A c ollaboration with Pfizer Inc. and global charitable foundation Wellcome was started in 2021 to better understand the role of diagnostics in advancing antimicrobial stewardship practices around the world. Building on ongoing efforts to advance the role of diagnostics in tackling the challenge of AMR, this collaboration will survey existing diagnostic practices to highlight both benefits of and gaps in diagnostic testing in AMR stewardship to improve and further advocate for patient care, clinical practice and health care economics. • In 2019, BD w as awarded grants from The Fleming Fund, a United Kingdom aid program designed to expand capacity for AMR diagnostics in 24 countries in sub-Saharan Africa and Asia, improving the surveillance of AMR and generating relevant data that is shared nationally and globally. Since the award, BD has helped to expand automated blood culture and identification, and antimicrobial susceptibility testing (ID/AST) technologies, to help strengthen laboratory systems for combating AMR. Our AMR solutions continue to be placed in countries with limited or no prior experience of using diagnostics to address AMR. In 2021, we began rolling out instruments to BD-awarded countries, a process that will be completed in 2022. 22 Antimicrobial Resistance Collaborators. “Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.” The Lancet . Published January 19, 2022. Accessed February 8, 2022. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02724-0/fulltext